ARMATA PHARMACEUTICALS, INC. Increase (Decrease) in Other Operating Assets and Liabilities, Net
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of -$153.00 thousand for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2020-08-13
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2020-06-30 was -$275.00K, a 427.38% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2020-03-31 was $122.00K, a 45.24% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2019-12-31 was $58.00K, a 18.31% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2019-09-30 was $84.00K, a 16.67% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for fiscal 2019 was $310.00K, a 8.01% increase from fiscal 2018.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in other operating assets and liabilities, net for fiscal 2018 was $287.00K.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2020-06-30 | -$275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$153.00K 10-Q · filed 2020-08-13 | -$95.00K derived: sum of 3 quarters · filed 2020-08-13 | -$11.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2020-03-31 | $122.00K 10-Q · filed 2020-05-14 | $180.00K derived: sum of 2 quarters · filed 2020-05-14 | $264.00K derived: sum of 3 quarters · filed 2020-05-14 | $348.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $142.00K derived: sum of 2 quarters · filed 2020-03-19 | $226.00K derived: sum of 3 quarters · filed 2020-08-13 | $310.00K 10-K · filed 2020-03-19 |
| 2019-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $168.00K derived: sum of 2 quarters · filed 2020-08-13 | $252.00K 10-Q · filed 2019-11-12 | $323.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $168.00K 10-Q · filed 2020-08-13 | $239.00K derived: sum of 3 quarters · filed 2020-08-13 | $311.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $84.00K 10-Q · filed 2020-05-14 | $155.00K derived: sum of 2 quarters · filed 2020-05-14 | $227.00K derived: sum of 3 quarters · filed 2020-05-14 | |
| 2018-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $143.00K derived: sum of 2 quarters · filed 2020-03-19 | $287.00K 10-K · filed 2020-03-19 | |
| 2018-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $216.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $144.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |